April 29, 2025

New Oral Option Approved for GCA

The FDA approved Rinvoq (upadacitinib) as the first and only oral Janus kinase inhibitor for the treatment of giant cell arteritis in adults, providing a steroid-sparing option for achieving sustained remission.

Conexiant

April 25, 2025

WHI Funding Restored After Uproar

"We are now working to fully restore funding to these essential research efforts."

Conexiant

April 25, 2025

FDA Approves Penpulimab-kcqx for NPC

The FDA approved penpulimab-kcqx for first line and previously treated recurrent or metastatic non-keratinizing nasopharyngeal carcinoma.

Conexiant

April 24, 2025

FDA Warns of Topical Finasteride Risks

The FDA has issued a safety alert on compounded topical finasteride products, citing adverse events and emphasizing the lack of regulatory approval or safety evaluation.

Conexiant

April 24, 2025

WHI Funding Cuts Threaten Research Continuity

HHS will terminate WHI Regional Center funding in September 2025.

Conexiant

April 23, 2025

FDA Targets Petroleum-Based Dyes in Food Supply

The FDA and HHS announced plans to eliminate petroleum-based synthetic food dyes, citing potential health risks and aligning with global safety standards.

Conexiant

April 23, 2025

More Data, Please: FDA to Novavax

Novavax reveals FDA's request for more clinical data if COVID-19 vaccine is approved and expresses confidence in approval based on discussions.

Reuters

April 21, 2025

New Prescription App Reduces Migraine Days

The FDA has authorized CT-132, the first prescription digital therapeutic for episodic migraine prevention, based on clinical trial data showing reduced monthly migraine days.

Conexiant

April 18, 2025

Intranasal Diazepam Gains Expanded Approval for Pediatric Patients

“Approval of an immediate-use intranasal diazepam treatment that can be given at any time—even while a child is actively seizing—in this young age group is an important advance for the epilepsy community.”

Conexiant